JP2024536106A - 骨形成不全症の治療における抗スクレロスチン抗体の使用方法 - Google Patents

骨形成不全症の治療における抗スクレロスチン抗体の使用方法 Download PDF

Info

Publication number
JP2024536106A
JP2024536106A JP2024518919A JP2024518919A JP2024536106A JP 2024536106 A JP2024536106 A JP 2024536106A JP 2024518919 A JP2024518919 A JP 2024518919A JP 2024518919 A JP2024518919 A JP 2024518919A JP 2024536106 A JP2024536106 A JP 2024536106A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sclerostin antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536106A5 (https=
Inventor
マキノン，アラステア
ミストリー，アルン
カッキス，エミル
オミンスキー，マイケル，エス．
Original Assignee
メレオ バイオファーマ ３ リミテッド
ウルトラジェニックス ファーマシューティカル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メレオ バイオファーマ ３ リミテッド, ウルトラジェニックス ファーマシューティカル インコーポレイテッド filed Critical メレオ バイオファーマ ３ リミテッド
Publication of JP2024536106A publication Critical patent/JP2024536106A/ja
Publication of JP2024536106A5 publication Critical patent/JP2024536106A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024518919A 2021-09-30 2022-09-29 骨形成不全症の治療における抗スクレロスチン抗体の使用方法 Pending JP2024536106A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163250918P 2021-09-30 2021-09-30
US63/250,918 2021-09-30
US202263374982P 2022-09-08 2022-09-08
US63/374,982 2022-09-08
PCT/US2022/077259 WO2023056355A2 (en) 2021-09-30 2022-09-29 Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta

Publications (2)

Publication Number Publication Date
JP2024536106A true JP2024536106A (ja) 2024-10-04
JP2024536106A5 JP2024536106A5 (https=) 2025-09-24

Family

ID=85783647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518919A Pending JP2024536106A (ja) 2021-09-30 2022-09-29 骨形成不全症の治療における抗スクレロスチン抗体の使用方法

Country Status (9)

Country Link
US (1) US20250011407A1 (https=)
EP (1) EP4408884A4 (https=)
JP (1) JP2024536106A (https=)
KR (1) KR20240082380A (https=)
AU (1) AU2022357544A1 (https=)
CA (1) CA3233220A1 (https=)
MX (1) MX2024003828A (https=)
TW (1) TW202323278A (https=)
WO (1) WO2023056355A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025212547A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Methods of treating osteogenesis imperfecta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517672A (ja) * 2008-03-24 2011-06-16 アボツト・バイオテクノロジー・リミテツド 骨損失を治療するための方法及び組成物
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
KR20190037261A (ko) * 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
US10961305B2 (en) * 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
GB201810746D0 (en) * 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist

Also Published As

Publication number Publication date
EP4408884A2 (en) 2024-08-07
TW202323278A (zh) 2023-06-16
AU2022357544A1 (en) 2024-04-11
CA3233220A1 (en) 2023-04-06
MX2024003828A (es) 2024-05-10
US20250011407A1 (en) 2025-01-09
WO2023056355A2 (en) 2023-04-06
EP4408884A4 (en) 2025-04-23
KR20240082380A (ko) 2024-06-10
WO2023056355A3 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
US12582712B2 (en) Method of making anti-pro/latent myostatin antibodies
US11925683B2 (en) Compositions for making and using anti-Myostatin antibodies
US20090060924A1 (en) Anti-sclerostin antibodies
AU2017299858B2 (en) Antibodies to Amyloid beta
CN111196849A (zh) 抗硬骨素抗体、其抗原结合片段及其医药用途
US20250011407A1 (en) Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
KR20240018471A (ko) 중등증 내지 중증 불완전 골형성증의 치료
CN116916958A (zh) 用于sars-cov-2感染的抗体疗法
JP2019089840A (ja) コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250912